investorr@investorr.eu
An innovative oral drug formulation for the treatment of hard-to-heal wounds and burns, invented in the United States. The drug has been tested with very good clinical trial results in an Asian country. A dossier for registration by the FDA and EMA is in preparation.
Various cooperation options possible for registration, market launch and production in the future.
The price of the license for the EU and US region will be determined in the negotiation process.
Area of origin: USA
Contact us for more details. Please use the form below.